Navigation Links
AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
Date:5/27/2009

AMSTERDAM, May 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-021 for the treatment of acute intermittent porphyria (AIP).

Orphan Drug Designation for AIP entitles AMT to ten year market exclusivity in Europe following marketing approval for AMT-021 if this product candidate is the first new drug with a major medical benefit receiving marketing approval for the European Union. The designation also provides for special benefits, including research support, eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of application for marketing approval.

"We are proud to have received this Orphan Drug Designation for the treatment of acute intermittent porphyria," said Sander van Deventer, Chief Executive Officer of AMT. "This designation is an important step in the development of a treatment for this seriously debilitating and potentially lethal disease."

About Acute Intermittent Porphyria

Acute intermittent porphyria is a rare genetic disease in which mutations in the PBGD gene result in insufficient activity of a protein necessary for the synthesis of heme. This leads to an accumulation of toxic intermediate metabolites resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric, neurologic illnesses, and muscular weakness. Long-term consequences may be irreversible nerve damage, liver cancer and kidney failure. Acute porphyric attacks can be life-threatening.

AIP affects 1 per 10.000 people in the European Union.

Currently available therapies do not prevent the symptoms and consequences of acute porphyric attacks. AMT has demonstrated that its prod
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANCISCO, Calif. , Aug. 27, 2015 /PRNewswire/ ... therapeutics for the treatment of cancer, today announced ... member of the company,s Board of Directors, has ... led immuno-oncology at Eli Lilly and AstraZeneca, and ... first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb ...
(Date:8/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... therapies, today announced that it will release its year-end ... 2015 on Friday, September 4, 2015. ... call and live webcast for investors, analysts and other ...
(Date:8/27/2015)... , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. (NASDAQ: ... PhD, Chief Executive Officer, will present a corporate overview and ... in New York City . , ... at 11:30 am ET at the Millennium Broadway Hotel. ... 3:00 pm ET at the St. Regis Hotel. ...
Breaking Medicine Technology:Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3SciClone To Present At Two Investor Conferences On September 10, 2015 2
... , NANJING , China ... SCR ), a leading manufacturer and supplier of ... (also known as Endu) in China , announced today ... conference in Beijing ,dedicated to this study. The New ...
... March 18 Jeffrey B. Kindler , ... chairman of the Pharmaceutical Research and Manufacturers of America ... elected were sanofi-aventis Chief Executive Officer Christopher Viehbacher ... and John C. Lechleiter , Ph.D., Chairman, President ...
Cached Medicine Technology:Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 2Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 3Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 4Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8
(Date:8/27/2015)... ... 27, 2015 , ... About 10 percent of mothers experienced ... Coast, killing more than 1,800 people, displacing hundreds of thousands and causing widespread ... study. , While most people don’t develop persistent depression after a major disaster ...
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a ... Patient Education content is ICD-10 ready and available to all clients. All Krames ... code sets, which are more targeted and return a more comprehensive data set ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... In addition ... Alvernia University now offers a third doctoral program at its main campus in Reading: ... a terminal degree program designed to prepare advanced practice nurses for the highest level ...
(Date:8/27/2015)... London, UK (PRWEB) , ... ... ... Ltd and Black Swan Analysis signed a partnership agreement for quality market ... sell research reports elaborated by Black Swan Analysis. , Commenting on the ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Sunbelt® Bakery, ... high fructose corn syrup, is changing the expectation of how protein bars should taste ... indulgent taste unlike any other protein bar on the market today. , The ...
Breaking Medicine News(10 mins):Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
... reduces the risk of heart disease. But almost everyone feels ... recent study shows that skinny people are also prone to ... factors in the genesis of various heart ailments. ,Dr. ... who headed the study, says that heart disease does not ...
... is playing havoc with the economies of,developed countries like ... of vaccinating the animals for the past three decades. ... regular basis is the best,means of preventing the spread ... joint,director of the Bangalore-based Indian Veterinary Research Institute (under,ICAR), ...
... research backed by the British government says that smoking will ... to come, surpassing the threat of even HIV. The British ... smoking will kill more people than any other disease in ... of Development Studies in Sussex, United Kingdom, says smoking and ...
... States of America has zeroed in on the culprit behind ... isolated which is said to be the cause for girls ... most widely held explanation for this is growing childhood obesity, ... were keen on the role of estrogen, a female hormone, ...
... are paranoid about heart disease. One survey said that of ... heart disease. Whenever people get to read something on heart ... worrying at times over trivial problems based on the assumption ... conducted in Austria says that chronic infections can predispose to ...
... A study conducted by Dr. Michael Brent, an associate ... St. Louis, gives us an insight into the way ... age.,These findings were presented at the annual meeting of ... San Francisco.,For years the ability of children to pick ...
Cached Medicine News:Health News:India takes on foot-and-mouth disease by vaccinating animals 2
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic. Economical. Single use. Non-Sterile....
... Portex® Blue Line® uncuffed endotracheal ... or Murphy styles, in standard ... Line® adult and pediatric uncuffed ... implant-tested polyvinyl chloride with a ...
... Portex® Blue Line® uncuffed endotracheal ... or Murphy styles, in standard ... Line® adult and pediatric uncuffed ... implant-tested polyvinyl chloride with a ...
Medicine Products: